FGFR2 identified as key driver in KRAS-mutated pancreatic cancer progression

Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 inactivation delayed KRAS-mutated PDAC development in mice.

Continue ReadingFGFR2 identified as key driver in KRAS-mutated pancreatic cancer progression